Healthcare - Biotechnology - NASDAQ - US
$ 25.7
1.3 %
$ 15.1 B
Market Cap
10.12
P/E
INCOME STATEMENT
2.35 B
REVENUE
1.49 B
OPERATING INCOME
1.13 B
NET INCOME
EFFICIENCY
Earnings Waterfall
Royalty Pharma plc
| Revenue | 2.35 B |
| Cost Of Revenue | 561 M |
| Gross Profit | 1.79 B |
| Operating Expenses | 862 M |
| Operating Income | 1.49 B |
| Other Expenses | 357 M |
| Net Income | 1.13 B |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 2 354.6 | 2 237.2 | 2 289.5 | 2 122.0 | 1 814.3 | 1 794.9 | 1 597.9 | 1 877.4 | 1 652.4 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 560.7 | 5.7 | 23.0 | 88.1 | 1 019.3 | 136.0 | 33.3 | 0 | 0 |
| Gross Profit | 1 793.9 | 2 231.5 | 2 266.5 | 2 033.9 | 794.9 | 1 658.9 | 1 564.7 | 1 877.4 | 1 652.4 |
| OPERATING INCOME | |||||||||
| Operating Expenses | 862.4 | 1 314.3 | 858.7 | 527.0 | (808.9) | 430.4 | 658.2 | 1 086.3 | 790.0 |
| Selling, General and Administrative Expenses | 249.7 | 227.3 | 182.8 | 182.0 | 103.4 | 61.9 | 106.4 | 69.5 | 121.4 |
| Research and Development Expenses | 52.0 | 177.1 | 200.1 | 26.0 | 83.0 | 392.6 | 117.9 | 91.0 | 98.4 |
| Operating Income | 1 492.2 | 977.5 | 1 430.7 | 1 595.0 | 2 623.2 | 1 364.4 | 939.7 | 722.9 | 794.3 |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 187.2 | 188.0 | 166.1 | 157.0 | 268.6 | 280.0 | 247.3 | 238.9 | 224.4 |
| Total Other Income | 207.9 | (77.0) | (189.5) | 106.6 | (161.8) | 153.4 | 403.5 | 39.0 | (35.6) |
| Pre-Tax Income | 1 700.1 | 230.1 | 1 241.2 | 1 702.0 | 2 461.4 | 1 517.9 | 1 343.2 | 761.9 | 758.7 |
| NET INCOME | |||||||||
| Tax Provision | 0 | 187.2 | 762.4 | 1 147.0 | 349.3 | 433.4 | 542.7 | 196.0 | 177.3 |
| Net Income | 1 134.8 | 42.8 | 478.8 | 495.2 | 2 348.5 | 1 377.7 | 1 210.0 | 565.9 | 581.4 |
| EPS | 3.41 | 0.0978 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |